Evidence map›Paper›PMID 42222338›Full record

ArticleFrontiers in cell and developmental biology2026

Understanding the link between PMN-MDSCs and CXCL8-CXCR1/2 axis in primary myelofibrosis.

Rita Campanelli, Stefania Mantovani, Christian Ramirez, Toma Tebaldi, Alessia La Gaipa, Claudia Del Fante, Carlotta Abbà, Adriana Carolei, Paolo Catarsi, Giovanni Barosi and 2 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rita CampanelliCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Stefania MantovaniDepartment of Translational and Clinical Research, Division of Molecular Medicine, Laboratory of Clinical Immunology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Christian RamirezLaboratory of RNA and Disease Data Science, Department of Cellular, Computational and Integrative Biology, University of Trento, Povo, Italy.
Toma TebaldiLaboratory of RNA and Disease Data Science, Department of Cellular, Computational and Integrative Biology, University of Trento, Povo, Italy.
Alessia La GaipaDepartment of Translational and Clinical Research, Division of Molecular Medicine, Laboratory of Clinical Immunology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Claudia Del FanteCell Manipulation Laboratory, Immunohaematology and Transfusion Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Carlotta AbbàCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Adriana CaroleiCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Paolo CatarsiCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Giovanni BarosiCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Margherita MassaGeneral Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Vittorio RostiCenter for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emergency myelopoiesis in cancer and chronic inflammation leads to the accumulation of myeloid-derived suppressor cells (MDSCs) which localize at tumor sites or areas of chronic inflammation, serving as suppressor cells. Besides reducing the cytotoxic functions of T/NK cells, these cells are major players of the inflammatory process that characterizes the onset and progression of cancer. Inflammation is thought to play a relevant role in the progression of primary myelofibrosis (PMF) and recent studies reported an increased frequency of circulating polymorphonuclear MDSCs (PMN-MDSCs) in these patients, especially in an advanced disease stage. Here, we describe an involvement of the axes CXCL8-CXCR1/2 and, at a lesser extent, CXCL12-CXCR4 in the occurrence of circulating PMN-MDSCs in patients. Our data suggest that, in PMF patients, the persistent inflammatory stimulus promotes the upregulation of CXCR1 expression on PMN-MDSCs (P = 0.024) compared with healthy subjects (HDs). A similar expression of CXCR1 is observed in the circulation of HDs treated with G-CSF (G-HDs) where the egression of MDSCs is related to the chemokine CXCL8. Moreover, the protein levels of CXCR4, an important factor in recruiting MDSCs, are elevated on PMN-MDSCs from PMF (P = 0.02) and G-HDs (P = 0.03) compared to controls, a pattern previously observed in solid cancers. Interestingly, in G-HDs the mobilization of PMN-MDSCs is a consequence of G-CSF stimulation and transient, while in PMF it is possibly mediated by the chronic inflammatory status characterizing the disease. These findings indicate that the overexpression of two distinct membrane receptors plays a prominent role in the biology of MDSCs in PMF.

Indexed as

CXCL12/CXCR4CXCL8/CXCR1CXCL8/CXCR2inflammationmyeloid-derived suppressor cellsprimary myelofibrosis

Identifiers

PMID42222338
PMCPMC13219034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.